Herpesvirus Antiviral Resistance
Database


    • TOP

    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology


    Mutations:

    Mutant Gene Virus Reference
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522L UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    V466G UL97 Human betaherpesvirus 5 Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    601-602del UL97 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    601-603del UL97 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)